Clinigen CFO Martin Abell to stand down

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 14:15

Pharmaceutical and services company Clinigen Group said its chief financial officer Martin Abell had resigned and would leave the business at the end of March.

He would replaced by Nick Keher, most previously head of Royal Bank of Canada's European healthcare equity research team.

Keher would take up the role from 19 March.

At 2:15pm: (LON:CLIN) Clinigen Group share price was -8.5p at 802.5p

Related content

Share price screen turns red again at ASOS

Netflix shareholders won’t enjoy looking at their trading screens this morning and neither will those of ASOS for precisely the same reason –...

Thu, 18/07/2019 - 11:34

Clinigen Group expects annual revenues to grow by 'at least' 19% amid boost from acquisitions

Clinigen Group, a pharmaceutical and services company, said it expected annual revenues to grow by 'at least' 19%, driven primarily by acquisitions.

For the...

Tue, 16/07/2019 - 08:55

Clinigen Group completes acquisition of the US rights to Proleukin

Clinigen Group completed the acquisition of the US rights to Proleukin following US anti-trust clearance.

'Proleukin is indicated for metastatic melanoma and metastatic renal...

Tue, 02/04/2019 - 10:05

Broker Forecast - RBC Capital Markets issues a broker note on Clinigen Group

RBC Capital Markets today reaffirms its top pick investment rating on Clinigen Group (LON:CLIN) and raised its price target to 1640p (from 1470p).

Broker Forecasts...

Wed, 27/02/2019 - 12:00

Clinigen profits slide as acquisitions costs weigh

Clinigen Group said Wednesday first-half profits declined as revenue growth was largely offset by costs related to acquisitions.

For the six months ended 31...

Wed, 27/02/2019 - 07:40